Savient to Sell Substantially All Assets To Crealta Pharmaceuticals for $120.4M

Savient Pharmaceuticals (NASDAQ: SVNT ) announced today that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million. The agreement